<DOC>
	<DOCNO>NCT00474084</DOCNO>
	<brief_summary>The purpose first feasibility study evaluate performance Vesta™ &amp; VestaCOR™ ( Hydroxy-Apetite coat GenX ) stent de novo native coronary artery lesion . This study provide long follow-up experience available . This randomized , double blind study conduct three site , two site India one The Netherlands . To eligible , patient require de novo stenotic lesion length could cover single stent native coronary artery diameter 3.0mm 3.5mm . A total least 60 patient maximum 70 patient treat Vesta™ &amp; VestaCOR™ stent . These patient randomize either smooth surface nanofilm coat stent ( = VestaCOR™ ) ( approx . 35 patient ) porous coat stent ( = Vesta™ ) ( approx . 35 patient ) . All patient follow clinically 30 day , 4 month , 9 month , 1 , 2 , 3 , 4 5 year .</brief_summary>
	<brief_title>Hydroxyapatite Active Pro Healing Clinical Trial Program</brief_title>
	<detailed_description />
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<criteria>Patient  18 year old Patient eligible percutaneous coronary intervention ( PCI ) Patient acceptable candidate CABG Clinical evidence ischemic heart disease and/or positive territorial functional study . Documented stable angina pectoris ( ( Canadian Cardiovascular Society ( CCS ) Classification 1 , 2 , 3 4 ) unstable angina pectoris document ischemia ( Braunwald Class IBC , IIBC , IIIBC ) , document silent ischemia The target lesion single de novo coronary artery lesion 50 100 % stenosis one major epicardial territory ( LAD , LCX RCA ) . A second target lesion another major epicardial vessel could treat second lesion fit inclusion/exclusion criterion receive type stent . The target lesion must cover one study stent preferably margin least 4mm side lesion The target lesion length ≤ 11 mm The target reference vessel diameter must  3.0mm  3.5mm Patient patient ’ legal representative inform nature study agree provision provide write informed consent approve Institutional Review Board/Ethics Committee respective clinical site Female childbearing potential Documented leave ventricular ejection fraction ( LVEF ) 30 % Evidence acute Qwave nonQwave myocardial infarction within 72 hour precede index procedure , unless CK CKMB enzymes less twice Upper Normal Limit Known allergy follow : aspirin , clopidogrel bisulfate ( Plavix® ) ticlopidine ( Ticlid® ) , heparin , Stainless Steel , contrast agent ( adequately premedicated ) drug similar hydroxyapatite A platelet count 100,000 cells/mm3 700,000 cells/mm3 WBC 3,000 cells/mm3 Acute chronic renal dysfunction ( creatinine 2.0 mg/dl 150µmol/L ) Total occlusion ( TIMI 0 1 ( one ) ) Target vessel evidence thrombus excessively tortuous make unsuitable proper stent delivery deployment ; Previous bare metal stenting ( less 1 year ) anywhere within target vessel Previous drugeluting stenting anywhere within target vessel ; The target lesion require treatment device PTCA prior stent placement ( e.g . limited , directional coronary atherectomy , excimer laser , rotational atherectomy , etc . ) Significant ( 50 % ) stenosis proximal distal target lesion might require revascularization impede run ; Heavily calcify lesion and/or calcify lesion successfully predilated Target lesion locate supplied arterial venous bypass graft Ostial target lesion Target lesion involve side branch 2.0mm diameter ostial disease Patient currently participate investigational drug device study Within 30 day prior procedure patient undergone previous coronary interventional procedure kind Within 60 day postprocedure patient require planned interventional treatment nontarget vessel . Planned intervention target vessel index procedure allow Stroke transient ischemic attack within prior 6 month Unprotected Left Main ( LM ) coronary artery disease ( stenosis &gt; 50 % ) In investigator ’ opinion patient comorbid condition ( ) could limit patient ’ ability participate study , compliance followup requirement impact scientific integrity study Planned surgery within 6 month index procedure Life expectancy less 1 year</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2007</verification_date>
	<keyword>Stent</keyword>
	<keyword>Hydroxyapatite</keyword>
	<keyword>Coronary Artery Stenosis</keyword>
	<keyword>Angioplasty</keyword>
</DOC>